4. Conclusion

Retinoblastoma survivors as carriers of the retinoblastoma gene have a long life and increased incidence for secondary tumors. Ophthalmologists should always keep this in mind to be able to provide these patients with proper counseling, plan for close long-term follow-up, and update their knowledge in the therapy modalities of retinoblastoma current management and possible secondary malignancies in adulthood. A clear consensus on the form of a screening protocol would be most appropriate and effective in preventing future malignancies.
